|
November 30 ,
2006
PRESS RELEASE
PEGASUS/HEARTVIEW'S
SCREENING DEVICE FOR HEART DISEASE RECEIVES MARKETING
APPROVAL FOR EUROPEAN UNION.
Palm Beach Gardens , FL ,
Market Wire, November 30 th , 2006. Pegasus/HeartView
LLC (Symbol: PGUZ-OTC) today announced that they have
received a CE Mark Approval for the marketing of their
6S Screening Device in Europe . The CE Mark Approval
authorizes Pegasus to commence a comprehensive marketing
effort throughout Europe and many other countries,
which recognize the CE Mark Approval.
In November, Pegasus/HeartView LLC participated
with one of its OEM European manufacturers in the world's
largest medical trade fair, the MEDICA 2006 SHOW, in
Dusseldorf, Germany (November 14 th to 17 th , 2006).
Pegasus/HeartView demonstrated the 6S Heart Screening
Device to hundreds of medical professionals and met
with several potential European distributors who will
participate in the marketing launch of the device,
which is an advanced, rapid and accurate screening
technology for early, non-invasive detection of heart
disease. For more information,
please contact Paul Davey, Investor Services at (778)
389-0915
( Canada ). Email: paul@pegasusbiosciences.com,
or Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals
Inc., Palm Beach Florida at (561) 626-9901.
Safe Harbor :
This news
release may include forward-looking statements within
the meaning of Section 27A of the United States Securities
Act of 1933, as amended, and Section 21E of the United
states Securities and Exchange Act of 1934, as amended
with respect to achieving corporate objectives, developing
additional project interests, the Company's analysis
of opportunities in the acquisition and development
of various project interests and certain other matters.
These statements are made under the 'safe
harbor' provisions of the United States Private Securities
Litigation Reform Act of 1995 and involve risks and
uncertainties which could cause actual results to differ
materially from those in the forward-looking statements
herein. |
